Ensysce Biosciences, Inc. (ENSC)
$
2.13
+0.08 (3.76%)
Key metrics
Financial statements
Free cash flow per share
-2.8146
Market cap
5 Million
Price to sales ratio
0.8356
Debt to equity
0.1253
Current ratio
2.1017
Income quality
0.9418
Average inventory
0
ROE
-1.5436
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on creating prescription drugs aimed at providing severe pain relief while addressing opioid addiction, misuse, abuse, and overdose in the United States. The gross profit stands at -$2,009,405.00 highlighting the company's profitability from core operations. The net income ratio is -1.53 reflecting the company's profitability margin, while the earnings per share (EPS) is reported at -$4.57 indicating the company's profitability on a per-share basis. The company incurred an income tax expense of $0.00 indicating its tax obligations, and the diluted EPS is -$4.57 accounting for potential share dilution. Ensysce employs innovative technologies like the Trypsin Activated Abuse Protection (TAAP) platform and the Multi-Pill Abuse Resistance (MPAR) platform in the development of its drug candidates. Currently, it is advancing PF614, a TAAP prodrug candidate of oxycodone, which is undergoing Phase II clinical trials for acute or chronic pain treatment. In addition, it is working on PF614-MPAR, a combination product of PF614 and nafamostat in Phase I trials aimed at overdose protection. The company also focuses on other candidates such as PF329, an extended-release prodrug of hydromorphone, and PF8001 and PF8026, prodrugs of amphetamine designed to combat ADHD medication abuse, along with PF26810, an extended-release prodrug of methadone for opioid use disorder, all of which are positioned to tackle key issues in pain management and opioid risks. The stock is affordable at $2.20 making it an attractive option for budget-conscious investors. With a high average trading volume of 392,200.00 the stock indicates strong liquidity, allowing for better buying and selling opportunities. It owns a market capitalization of $5,049,591.00 categorizing the company as a small-cap player in the market. Ensysce is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in its field. The company's commitment to addressing critical challenges in pain management through advanced pharmaceutical solutions positions it favorably within the industry.
Is Ensysce Biosciences, Inc. (ENSC) a good investment?
Investing in Ensysce Biosciences, Inc. (ENSC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Ensysce Biosciences, Inc. (ENSC)'s stock forecast?
Analysts predict Ensysce Biosciences, Inc. stock to fluctuate between $1.62 (low) and $14.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ensysce Biosciences, Inc.'s market capitalization?
As of 2025-08-19, Ensysce Biosciences, Inc.'s market cap is $5,049,591, based on 2,370,700 outstanding shares.
How does Ensysce Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ensysce Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ensysce Biosciences, Inc. (ENSC) stock?
To buy Ensysce Biosciences, Inc. (ENSC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENSC. Place an order (Market, Limit, etc.).
What is the best time to invest in Ensysce Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Ensysce Biosciences, Inc. stock ever split?
Ensysce Biosciences, Inc.'s last stock split was 1:15 on 2024-12-06.
How did Ensysce Biosciences, Inc. perform in the last earnings report?
Revenue: $5,210,000 | EPS: -$4.57 | Growth: -2.56%.
Where can I find Ensysce Biosciences, Inc.'s investor relations reports?
Visit https://www.ensysce.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ensysce Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Ensysce Biosciences, Inc. stock?
All-time high: $25,200 (2021-12-23) | All-time low: $1.62 (2025-04-21).
What are the key trends affecting Ensysce Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
New York, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business updates, management commentary, financial results, valuation, and risks.
accessnewswire.com
Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the first quarter ended March 31, 2025. Dr Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are pleased with the meaningful strides the Company has continued to make in the first quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.
benzinga.com
Ensysce Biosciences, Inc ENSC stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.
accessnewswire.com
SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.
accessnewswire.com
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team continued to make significant strides in the fourth quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.
prnewswire.com
NEW YORK , March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS , Program Director with Creighton University . The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.
See all news
